305 results match your criteria: "Hôpital Universitaire Dupuytren[Affiliation]"

Toxoplasma gondii from Gabonese forest, Central Africa: First report of an African wild strain.

PLoS Negl Trop Dis

January 2025

Inserm U1094, IRD UMR270, Univ. Limoges, CHU Limoges, EpiMaCT - Epidemiology of Chronic Diseases in Tropical Zone, Institute of Epidemiology and Tropical Neurology, OmegaHealth, Limoges, France.

The protozoan Toxoplasma gondii is a ubiquitous and highly prevalent parasite that can theoretically infect all warm-blooded vertebrates. In humans, toxoplasmosis causes infections in both immunodeficient and immunocompetent patients, congenital toxoplasmosis, and ocular lesions. These manifestations have different degrees of severity.

View Article and Find Full Text PDF

Objective: To evaluate the prognostic impact of circulating tumor DNA (ctDNA) detection at diagnosis (T0) and its early decrease after one cycle (T1) of neoadjuvant chemotherapy (NACT) in patients with advanced epithelial ovarian cancer (EOC) included in the CHIVA trial (NCT01583322).

Methods: Blood samples were collected at T0 and before each administration of NACT. Circulating tumor DNA detection was performed by next-generation sequencing.

View Article and Find Full Text PDF

Laboratory practices for the diagnosis and management of mucormycosis in France, 2024.

J Mycol Med

December 2024

Laboratoire de Parasitologie-Mycologie, Hôpital Européen Georges Pompidou, Hôpital Universitaire Necker, Unité de Parasitologie-Mycologie, Service de Microbiologie, Paris, France. Electronic address:

This study investigates the diagnostic practices for mucormycosis among 30 French University Hospital mycology laboratories, in 2024. All laboratories perform both direct examination and culture, with fluorescent brighteners being the most commonly used method for direct examination. While 77 % of the participating laboratories routinely identify Mucorales to the species level, with 70 % having adopted Mucorales-specific quantitative PCR, primarily for the diagnosis of invasive fungal infections.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the effectiveness of combined treatment with anti-PD-1 (nivolumab) and anti-CTLA-4 (ipilimumab) antibodies compared to standard platinum-based chemotherapy in older patients with advanced non-small-cell lung cancer (NSCLC).
  • It focuses specifically on patients aged 70 years or older or those with an ECOG performance status of 2, as there is limited data on this demographic.
  • The trial is a phase 3 randomized controlled study conducted across 30 sites in France, aiming to evaluate overall survival, progression-free survival, and safety of the treatments in the intended patient population.
View Article and Find Full Text PDF

Reclassification of CTO Crossing Strategies in the ERCTO Registry According to the CTO-ARC Consensus Recommendations.

JACC Cardiovasc Interv

October 2024

Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Italy. Electronic address:

Article Synopsis
  • The CTO-ARC identified the need for standardized definitions in chronic total occlusion (CTO) procedures to avoid bias in attributing complications to different crossing strategies.
  • A study analyzed data from 8,673 patients in the European Registry of Chronic Total Occlusions, finding that the antegrade approach was used in 79.2% of cases, while retrograde was used in 20.8%.
  • Results showed that alternative antegrade crossing had lower technical success rates and higher complication rates compared to true antegrade and retrograde methods, though it was primarily used as a rescue strategy in most instances.
View Article and Find Full Text PDF

Doxorubicin-Trabectedin with Trabectedin Maintenance in Leiomyosarcoma.

N Engl J Med

September 2024

From the Departments of Medical Oncology (P.P., A.L.C.), Radiology (C.B.), and Biostatistics and Epidemiology (B.A.), Institut Gustave-Roussy, and Oncostat, INSERM Unité 1018, Labeled Ligue Contre le Cancer (B.A.), Villejuif, the Department of Medical Oncology, Institut Bergonié, and the Faculty of Medicine, University of Bordeaux, Bordeaux (A.I.), the Department of Medical Oncology, Institut Curie (S.P.-N.), and the Department of Medical Oncology, Hôpital Cochin-Port Royal (P.B.-R.), Paris, the Department of Medical Oncology, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse (C.C.), Lille University, and the Department of Medical Oncology, Centre Oscar Lambret, Lille (N.P.), the Department of Medical Oncology, Institut Régional du Cancer, INSERM Unité 1194, Institut de Recherche en Cancérologie de Montpellier, and the University of Montpellier, Montpellier (N.F.), the Department of Medical Oncology, Institut Paoli-Calmettes (F.B.), the Department of Medical Oncology, La Timone University Hospital (F.D.), and Aix-Marseille Université (F.B., F.D.), Marseille, the Department of Medical Oncology, Centre Hospitalo-Universitaire Dupuytren, Limoges (V.L.-L.), the Department of Medical Oncology, Centre Léon Bérard, and University Claude-Bernard Lyon 1, Lyon (I.R.-C.), the Department of Medical Oncology, Centre Hospitalier Universitaire de Besançon-Hôpital Jean-Minjoz, Besançon (E.K.), Institut de Cancérologie de l'Ouest, Angers-Nantes (E.B.), Institut de Cancérologie de la Loire, Saint-Priest-en-Jarez (O.C.), Centre Georges-François Leclerc, Dijon (N.I.), the Department of Medical Oncology, Centre Paul Papin, Rouen (C.G.), and Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy (M.R.) - all in France.

Article Synopsis
  • A phase 3 trial was conducted to compare the effectiveness of doxorubicin alone versus the combination of doxorubicin and trabectedin in treating advanced leiomyosarcoma.
  • The trial involved 150 patients and showed that those receiving the combination therapy had a longer median overall survival (33 months) compared to those receiving doxorubicin alone (24 months), with lower death rates in the combination group.
  • While the combination treatment improved progression-free survival (12 months vs. 6 months), it also led to a higher incidence of adverse events and dose reductions compared to doxorubicin alone.
View Article and Find Full Text PDF

Background: Ovarian cancer (OC) remains one of the most challenging and deadly malignancies facing women today. While PARP inhibitors (PARPis) have transformed the treatment landscape for women with advanced OC, many patients will relapse and the PARPi-resistant setting is an area of unmet medical need. Traditional immunotherapies targeting PD-1/PD-L1 have failed to show any benefit in OC.

View Article and Find Full Text PDF

This open-label, non-comparative, 2:1 randomized, phase II trial (NCT03275506) in women with stage IIIC/IV high-grade serous carcinoma (HGSC) for whom upfront complete resection was unachievable assessed whether adding pembrolizumab (200 mg every 3 weeks) to standard-of-care carboplatin plus paclitaxel yielded a complete resection rate (CRR) of at least 50%. Postoperatively patients continued assigned treatment for a maximum of 2 years. Postoperative bevacizumab was optional.

View Article and Find Full Text PDF

Purpose: The efficacy of the 1-h bundle for emergency department (ED) patients with suspected sepsis, which includes lactate measurement, blood culture, broad-spectrum antibiotics administration, administration of 30 mL/kg crystalloid fluid for hypotension or lactate ≥ 4 mmol/L, remains controversial.

Methods: We carried out a pragmatic stepped-wedge cluster-randomized trial in 23 EDs in France and Spain. Adult patients with Sepsis-3 criteria or a quick sequential organ failure assessment (SOFA) score ≥ 2 or a lactate > 2 mmol/L were eligible.

View Article and Find Full Text PDF

Background: CASSIOPEIA part 1 demonstrated superior depth of response and prolonged progression-free survival with daratumumab in combination with bortezomib, thalidomide, and dexamethasone (D-VTd) versus bortezomib, thalidomide, and dexamethasone (VTd) alone as an induction and consolidation regimen in transplant-eligible patients newly diagnosed with myeloma. In CASSIOPEIA part 2, daratumumab maintenance significantly improved progression-free survival and increased minimal residual disease (MRD)-negativity rates versus observation. Here, we report long-term study outcomes of CASSIOPEIA.

View Article and Find Full Text PDF

Curative criteria for endoscopic treatment of colorectal cancer.

Best Pract Res Clin Gastroenterol

February 2024

Department of Endoscopy and Gastroenterology, Centre Hospitalier Universitaire Dupuytren, Limoges, France. Electronic address:

As endoscopic treatment enables en bloc resection of T1 colorectal cancers, the risk of recurrence, often assimilated to the risk of lymph node metastases, must be assessed in order to offer patients an additional treatment if this risk is deemed significant. The curative criteria currently used by most guidelines are depth of invasion <1 mm, well or moderately differentiated tumour, absence of lympho-vascular invasion, absence of significant budding and tumour-free resection margins. However, these factors must be assessed by qualified pathologists, as they are difficult to evaluate.

View Article and Find Full Text PDF

Malignant distal biliary obstructions are becoming increasingly common, especially in patients with cancers of the pancreatic head, despite progress in medical oncology research. ERCP is the current gold standard for management of such strictures, but the emergence of EC-LAMS has rendered EUS-CDS both safe and efficient. It is a "game changer"; originally intended for ERCP failure, two randomised clinical trials recently proposed EUS-CDS as a first-intent procedure in palliative settings.

View Article and Find Full Text PDF
Article Synopsis
  • One-third of COVID-19 patients deteriorate after emergency department admission, necessitating effective prognosis assessments to predict worsening conditions.
  • Current predictive biomarkers include lymphopenia and the PaO2/FiO2 ratio, while markers like immature granulocytes and monocyte differentiation did not show predictive value.
  • A combined score using decreased P/F ratio, lymphopenia, and loss of mHLA-DR proved effective in predicting patient outcomes, pointing to the importance of early immunosuppression monitoring in COVID-19 cases.
View Article and Find Full Text PDF

Infections Differ Among Human Immunodeficiency Virus (HIV)-Seropositive and HIV-Seronegative Individuals: Results From a Nationwide Surveillance Program in France.

Open Forum Infect Dis

February 2024

Department of Infectious Diseases and Tropical Medicine, Université Paris Cité, Necker-Enfants Malades University Hospital, Assistance Publique-Hôpitaux de Paris, Institut Hospitalo-Universitaire Imagine, Paris, France.

Among 1107 cryptococcosis cases from the French surveillance network (2005-2020), the proportion of HIV-seronegative individuals has recently surpassed that of HIV-seropositive individuals. We observed marked differences in patient characteristics, disease presentations, cryptococcal antigen results, infecting species, and mortality according to HIV serostatus.

View Article and Find Full Text PDF

Background: The results of the PRODIGE 42/GERICO 12 study showed that short course radiotherapy had a better tolerance profile than radiochemotherapy, with comparable oncological results. We have included Quality of Life analyses and oncogeriatric evaluations in this study.

Patients And Methods: In all, 101 patients ≥75 years of age with resectable T3-T4 rectal adenocarcinoma less than 12 cm from the anal margin received short course radiotherapy (5X5 Gy in one week) or radiochemotherapy (50 Gy, 2 y/f and capecitabine 800 mg/m, 5 days/week) with delayed surgery (7 weeks ± 1) in both groups.

View Article and Find Full Text PDF

Beyond MEN1, When to Think About MEN4? Retrospective Study on 5600 Patients in the French Population and Literature Review.

J Clin Endocrinol Metab

June 2024

CHU Lille, Service de Biochimie et Biologie moléculaire « Hormonologie, Métabolisme-Nutrition, Oncologie, 59000 Lille, France.

Context: Germline CDKN1B variants predispose patients to multiple endocrine neoplasia type 4 (MEN4), a rare MEN1-like syndrome, with <100 reported cases since its discovery in 2006. Although CDKN1B mutations are frequently suggested to explain cases of genetically negative MEN1, the prevalence and phenotype of MEN4 patients is poorly known, and genetic counseling is unclear.

Objective: To evaluate the prevalence of MEN4 in MEN1-suspected patients and characterize the phenotype of MEN4 patients.

View Article and Find Full Text PDF

The use of peripheral blood (PB) or bone marrow (BM) stem cells graft in haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide (PTCy) for graft-versus-host disease (GVHD) prophylaxis remains controversial. Moreover, the value of adding anti-thymoglobulin (ATG) to PTCy is unknown. A total of 1344 adult patients received an unmanipulated haploidentical transplant at 37 centers from 2012 to 2019 for hematologic malignancy.

View Article and Find Full Text PDF

Genotyping of European Toxoplasma gondii strains by a new high-resolution next-generation sequencing-based method.

Eur J Clin Microbiol Infect Dis

February 2024

Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, Institute of Epidemiology, Greifswald - Insel Riems, Germany.

Purpose: A new high-resolution next-generation sequencing (NGS)-based method was established to type closely related European type II Toxoplasma gondii strains.

Methods: T. gondii field isolates were collected from different parts of Europe and assessed by whole genome sequencing (WGS).

View Article and Find Full Text PDF

Background And Aim: Germline mutations of telomere-related genes (TRG) induce multiorgan dysfunction, and liver-specific manifestations have not been clearly outlined. We aimed to describe TRG mutations-associated liver diseases.

Approach And Results: Retrospective multicenter analysis of liver disease (transaminases > 30 IU/L and/or abnormal liver imaging) in patients with TRG mutations.

View Article and Find Full Text PDF

[Bronchoscopic COPD treatments].

Rev Mal Respir

December 2023

Service de pneumologie, hôpital Maison Blanche, Inserm UMRS-1250, université Reims Champagne Ardenne, Reims, France.

Introduction: Chronic obstructive pulmonary disease (COPD) is associated with disabling respiratory symptoms including dyspnea, frequent exacerbations and chronic bronchitis. The currently available pharmacological and non-pharmacological therapies have limited efficacy, necessitating the development of interventional strategies, many of them endoscopic.

State Of The Art: Endoscopic lung volume reduction has markedly increased over recent years, principally as regards the endobronchial valves currently used in routine care.

View Article and Find Full Text PDF
Article Synopsis
  • A multicentre retrospective study of 220 adult patients undergoing allogeneic hematopoietic stem cell transplantation (alloHSCT) for therapy-related acute myeloid leukaemia (t-AML) reveals a median diagnosis age of 56 years and a significant history of prior hematological conditions or breast cancer.
  • At 12 months post-transplant, overall survival (OS) was 60.7%, event-free survival (EFS) was 52.8%, and graft-versus-host disease-free relapse-free survival (GRFS) was 44.1%; 44% of patients achieved complete remission by last follow-up.
  • The study indicates that uncontrolled t-AML at the time of transplant negatively impacts E
View Article and Find Full Text PDF

A dual function for the chromatin organizer Special A-T rich Binding Protein 1 in B-lineage cells.

Cell Mol Immunol

October 2023

Laboratoire Contrôle de la Réponse Immune B et des Lymphoproliférations (CRIBL), Université de Limoges, CNRS Unité Mixte de Recherche 7276, Inserm Unité 1262, Limoges, France.

SATB1 (Special A-T rich Binding protein 1) is a cell type-specific factor that regulates the genetic network in developing T cells and neurons. In T cells, SATB1 is required for lineage commitment, VDJ recombination, development and maturation. Considering that its expression varies during B-cell differentiation, the involvement of SATB1 needs to be clarified in this lineage.

View Article and Find Full Text PDF